By using phage-display technology, Rios-Doria and colleagues developed another ADAM17 inhibitory antibody, MEDI3622, that blocked ADAM17 activity, and consequently, release of TNF in LPS-stimulated mice and tumor progression in a head and neck patient-derived xenograft model [214]. The gene discussed is ADAM17; the disease is neoplasm.